Extended Data Table 2 PFS by PD-L1 CPS in the safety analysis set

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  1. Efficacy was assessed as an exploratory analysis in cohort 4 A + 4B. One patient was missing a value for CLDN18.2 expression. Two patients were missing PD-L1 CPS values.
  2. aDefined as ≥75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.CLDN18.2, claudin 18 isoform 2; CPS, combined positive score; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1; PFS, progression-free survival.
Back to article page